Addition of 400 microgram misoprotol to routine management of third stage of labour in women at risk for bleeding after delivery.
Not Applicable
Recruiting
- Conditions
- Health Condition 1: null- Pregant women with known High risk factors for post partum hemorrhage.
- Registration Number
- CTRI/2014/03/004491
- Lead Sponsor
- RS MEDICAL COLLEGE KOLKATA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
Women with one or more of the high risk factors as
multiple pregnancy
•polyhydramnios
•prolonged labour
•labor augmented by oxytocin.
•H/O PPH in previous pregnancy.
•Post caesarean section (for vaginal delivery)
•Obese patient (BMJ >30)
•Grand multipara
•APH
•Severe preeclampsia/eclampsia.
•Anaemia(hb <10gm%)
Exclusion Criteria
Any contraindications for the use of misoprostol and oxytocin such as known hypersensitivity, asthma, epilepsy etc.
Cardiovascular, hepatic, haematological disorders.
Temperature >38ï?°C
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood loss after delivery and incidence of Post partum HaemorrhageTimepoint: From delivery of the newborn to 1 hour after delivery
- Secondary Outcome Measures
Name Time Method 1.Post parum drop of Haemoglobin concentration <br/ ><br>2. need for additional oxytocic and blood transfusion <br/ ><br>3. complications and side effectsTimepoint: 1. 24 hours after delivery <br/ ><br>2. 24 hours after delivery <br/ ><br>3. 24 hours after delivery
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie misoprostol's efficacy in preventing postpartum hemorrhage in high-risk women?
How does sublingual misoprostol compare to intravenous oxytocin in managing third stage of labor for postpartum hemorrhage prevention?
Are there specific biomarkers that predict response to misoprostol in high-risk postpartum hemorrhage patients following vaginal delivery?
What are the known adverse events associated with sublingual misoprostol administration during labor and how are they managed?
What combination therapies or alternative prostaglandin analogs show promise in postpartum hemorrhage prevention alongside standard care?